- Home
- ODV vs GNFT Comparison
ODV vs GNFT Comparison
Compare ODV & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODV
- GNFT
- Stock Information
- Founded
- ODV 2005
- GNFT 1999
- Country
- ODV Canada
- GNFT France
- Employees
- ODV N/A
- GNFT N/A
- Industry
- ODV Precious Metals
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ODV Basic Materials
- GNFT Health Care
- Exchange
- ODV Nasdaq
- GNFT Nasdaq
- Market Cap
- ODV 193.9M
- GNFT 180.2M
- IPO Year
- ODV N/A
- GNFT 2019
- Fundamental
- Price
- ODV $1.49
- GNFT $3.67
- Analyst Decision
- ODV
- GNFT Strong Buy
- Analyst Count
- ODV 0
- GNFT 1
- Target Price
- ODV N/A
- GNFT $13.00
- AVG Volume (30 Days)
- ODV 484.0K
- GNFT 9.3K
- Earning Date
- ODV 05-05-2025
- GNFT 04-24-2025
- Dividend Yield
- ODV N/A
- GNFT N/A
- EPS Growth
- ODV N/A
- GNFT N/A
- EPS
- ODV N/A
- GNFT 0.47
- Revenue
- ODV $8,487,361.00
- GNFT $86,225,222.00
- Revenue This Year
- ODV N/A
- GNFT $145.20
- Revenue Next Year
- ODV $479.40
- GNFT N/A
- P/E Ratio
- ODV N/A
- GNFT $7.66
- Revenue Growth
- ODV N/A
- GNFT 175.45
- 52 Week Low
- ODV $1.16
- GNFT $3.11
- 52 Week High
- ODV $2.75
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- ODV 54.28
- GNFT 52.36
- Support Level
- ODV $1.44
- GNFT $3.35
- Resistance Level
- ODV $1.59
- GNFT $3.63
- Average True Range (ATR)
- ODV 0.08
- GNFT 0.09
- MACD
- ODV 0.02
- GNFT 0.01
- Stochastic Oscillator
- ODV 66.67
- GNFT 88.89
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation and development activities of its projects.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.